Ridley, J., Manyweathers, S., Tang, R., Goetze, T., Becker, N., Kirby, R., Obergrussberger, A., & Rogers, M. (2022). Development of ASIC1a ligand-gated ion channel drug screening assays across multiple automated patch clamp platforms. Frontiers in Molecular Neuroscience. Frontiers in Molecular Neuroscience, 2022.https://www.frontiersin.org/journals/molecular-neuroscience/articles/10.3389/fnmol.2022.982689/full
Metrion Biosciences is a specialist ion channel contract research organisation providing drug discovery services to pharmaceutical and bioscience customers worldwide. Discover more about our capabilities and facilities in this short introductory video.
Transient receptor potential (TRP) channels are a family of ion channels distantly related to the voltage-gated superfamilies
The voltage-gated potassium channel family is composed of forty members and they are separated into twelve classes Kv1 to Kv12
The voltage-gated sodium channel family is composed of nine pore-forming members, which are named Nav1.1 to Nav1.9 and encoded by genes referred to as SCN1A to SCN11A
Dr. Kris Kahlig is the Head of Biology at Praxis Precision Medicines Inc. a clinical stage biopharmaceutical company translating genetic insights into the development of therapies for patients affected by CNS disorders. Kris presented at the Metrion Webinar series on “Using Dynamic Action Potential Clamp Modelling of Nav1.2 Variants to Support the Prediction of Clinical Phenotype in DEE”.
The webinar took place on Thursday 5th May 2022 at 16:00 BST.
We are delighted to present the fourth speaker in our “Ion Channels in Drug Discovery” webinar series – Dr. Greg Carr from the Lieber Institute for Brain Development. Greg’s presentation was entitled: “A role for hERG potassium channels in cognitive function”
The webinar took place on Thursday 3rd February 2022 at 16:00 BST.
We are delighted to present the third speaker in our webinar series – Professor David Sheppard from the University of Bristol. David’s presentation was focused on Cystic Fibrosis and his talk was “Cystic Fibrosis: Rescuing Faulty Channels with Targeted Therapies”.
The webinar took place on Tuesday 30th November 2021 at 16:00 BST.
Nonclinical safety pharmacology studies for siRNA follow a hybrid of the small molecule (SM) guidance and biologics guidance. The Oligonucleotide Safety Working Group (OSWG) has published a series of recommendation papers for oligonucleotides, including recommendations for safety assessment, because development of oligonucleotide-based therapeutics is not addressed by regulations. This is especially true regarding the hERG assay, which is a core assay in ICH S7B for SM. While OSWG states that a hERG study is not necessary for IND submission, all approved siRNAs have submitted hERG data which are necessary for requesting a TQT waiver.
We are delighted to present the second speaker in our webinar series – Professor Stephen Tucker from the Department of Physics at the University of Oxford. Stephen speaking on the topic of the TASK-1 K2P channel and his talk will be entitled “Defective X-gating caused by de novo mutations in the TASK-1 K2P channel (KCNK3) underlies a developmental disorder with sleep apnea”.
The webinar took place on Thursday 16th September 2021 at 16:00 BST.